Adjuvant Chemotherapy Improves Survival in Diffuse Malignant Peritoneal Mesothelioma

This retrospective study evaluated the effects of perioperative treatment options in 126 patients with diffuse malignant peritoneal mesothelioma (DMPM) undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). The 5-year overall survival was significantly different among the perioperative treatment groups: 40% in patients receiving neoadjuvant chemotherapy, 67% in patients receiving adjuvant chemotherapy, 62% in patients receiving perioperative chemotherapy, and 56% in patients receiving no chemotherapy before or after CRS-HIPEC. Major complications occurred in approximately 40% of patients in each group. Worse overall survival was significantly associated with receiving neoadjuvant chemotherapy (HR, 2.30; 95% CI, 1.07–4.94; P = .033).

This study suggests that neoadjuvant chemotherapy may decrease overall survival while adjuvant chemotherapy may improve survival in patients with DMPM who undergo CRS-HIPEC.

Source: Adjuvant Chemotherapy Improves Survival in Diffuse Malignant Peritoneal Mesothelioma


 Mesothelioma, Asbestos, and Legal Compensation: Basic Facts

Asbestos-Mesothelioma Case Evaluation Form
Free.  Confidential.  No Obligation.

Speak Your Mind

*

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, NC 28403
Tel: (800) 426-9535
Email@LambLawOffice.com
Disclaimer and Copyright